Prosopagnosia

Summary

Prosopagnosia (MONDO:0003227) is a disease. A subtype of agnosia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	prosopagnosia
Mondo ID	MONDO:0003227
MeSH	D020238
DOID	DOID:4970
ICD-11	858616900
NCIT	C85031
UMLS	C0234512
MedGen	65884
GARD	0027636
Is cancer (heuristic)	no

Also known as: face blindness · prosopagnosia · prosopagnosia (disease)

Data availability: 1 HPO phenotype.

Disease family

This is a subtype of agnosia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › perceptual disorders › agnosia › prosopagnosia

Related subtypes (19): akinetopsia, alexithymia, amusia, anosognosia, auditory agnosia, autotopagnosia, cortical deafness, finger agnosia, integrative agnosia, mirror agnosia, pain agnosia, phonagnosia, semantic agnosia, simultanagnosia, social emotional agnosia, astereognosia, tactile agnosia, time agnosia, visual agnosia

Subtypes (1): prosopagnosia, hereditary

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.